Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8%

Stevanato Group SpA (STVN) reported Q3 2026 revenue growth of 8%, but expects lower GLP-1 volumes in 2027 from a single customer, moderating growth. Engineering segment revenue declined 12%, and gross profit margin decreased to 29.1%. The company backfilled most GLP-1 shortfall but expects validation delays. Non-GLP biologics grew 30% in Q3, driven by broad engagement and capacity investments. Alina pen injector and other delivery devices are in validation stages.

Original reporting

finance.yahoo.com

Published Nov 3, 2026, 9:07 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 3, 2026, 9:25 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · finance.yahoo.com

Decision brief

The 30-second read

$STVNBearishMed

Why it matters

Earnings call provides first‑time guidance adjustments for 2027 and detailed segment performance, shaping short‑term price expectations.

Market read

New guidance and volume outlook create actionable insight for traders focused on specialty pharma equipment stocks.

What to watch

Take‑or‑pay contracts and capacity reservations may cushion volume shortfalls more than management suggests.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Stevanato Group is an Italian manufacturer of injectable drug delivery devices, listed on NYSE under STVN.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$STVNBearishHigh confidence

Context

Q3 2026 earnings call disclosed lower GLP-1 volumes in 2027, trimmed engineering revenue guidance, and a 12.2% organic BDS growth.

Expected impact

likely pressure as investors price in slower 2027 growth and lower engineering revenue.

Evidence & confidence

The earnings call provides fresh guidance and volume shortfall data that were not previously public, directly affecting valuation.

Market effects

Sector

Highlights softness in GLP‑1 syringe market, potentially affecting peers in injectable drug delivery.

Regional

European pharma equipment suppliers may see similar margin pressure from utility cost spikes.

Global

Limited to specialty pharma equipment niche; broader market impact modest.

Counterpoint

What could challenge this read

The strong 30% growth in non‑GLP biologics and Fishers breakeven could offset GLP‑1 headwinds, supporting a buy‑on‑dip thesis.

Key entities

Executive Chairman
Franco Stevanato
Provided commentary on GLP‑1 volume headwinds and strategic focus.
CFO
Marco Dal Lago
Discussed compensation, BDS growth, and utility cost impacts.

Read at source ← All news

Med

UBS maintains Stevanato Group at Neutral, lowers price target to $16 from $23

UBS kept Stevanato Group at Neutral but cut its price target to $16 from $23, a 30.4% reduction. This implies a 19.0% upside from the Nov 4 close of $13.44.

tradingview.comNov 4

$STVNHighAI 8/10

Stevanato Group Q3 Earnings Call Highlights

Stevanato Group (STVN) expects 2027 revenue growth to moderate to low-single-digit due to GLP-1-related headwinds, but believes growth will normalize beyond 2027. The company reaffirmed its 2026 guidance, forecasting revenue of €1.26B-€1.28B and adjusted EBITDA of €335M-€345.2M. It is ramping up manufacturing investments and working on over 50 GLP-1-related programs with 30 global customers.

finance.yahoo.comNov 4

$STVNMed

Stevanato (STVN) Q3 2026 Earnings Call Transcript

Stevanato (STVN) reported Q3 2026 earnings, with non-GLP biologics revenue up 30% offsetting GLP-1 declines. Full-year non-GLP biologics revenue rose 13%. The company expects lower GLP volumes in 2027 but strong demand in non-GLP biologics. They are backfilling revenue and expanding production capacity. Engineering segment results were below expectations, but BDS segment performance will offset this.

finance.yahoo.comNov 3

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q3 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) – November 3, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug de

SEC EDGAR 6-KNov 3

HighAI 8/10

Why is Stevanato stock plunging today?

Stevanato Group's stock fell 25.5% to $14.71 after reporting Q3 2026 revenue of €326.1M, up 8% YoY, beating estimates. However, the outlook for 2027 revenue growth was cut to low single digits due to reduced GLP-1-related volumes from a large customer, alarming investors. The company maintained its full-year 2026 revenue guidance of €1.26B to €1.28B.

investing.comNov 3

$STVNHighAI 9/10

Stevanato Group Stock Plunges 26% as Weak Order Intake and Cautious 2027 Outlook Overshadow Revenue Beat

Stevanato Group (STVN) shares dropped 26% after reporting Q3 revenue growth of 8% to 326.1M euros, beating expectations, but providing a cautious 2027 outlook with low single-digit revenue growth. Adjusted EPS was 16 euro cents, in line with estimates. The company's market value fell to $4B. GLP-1 therapy revenue was 17-18% of total revenue, with other biologics growing over 30%. The Engineering segment saw a 12% revenue decline.

ibtimes.com.auNov 3